Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01592240 · ClinicalTrials.gov registry record · Phase 2
Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 354
- Enrollment target
NCT01592240 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 354 participants.
The verdict
NCT01592240, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 354 participants
- Enrollment target
Study Summary
To evaluate the Low Density Lipoprotein-Cholesterol (LDL-C) lowering effect of PF-04950615 administered subcutaneously at monthly intervals, or twice monthly intervals in subjects with high cholesterol whose LDL-cholesterol is \>/=80 mg/dL on background treatment with a statin.
Interventions
- DRUG PBO
- DRUG 200mg PF-04950615 (RN316)
- DRUG 300mg PF-04950615 (RN316)
- DRUG PF-04950615
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 354 participants |
| Start Date | 2012-07 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01592240
The ClinicalTrials.gov registry entry for NCT01592240 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 354 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which PBO is the first listed.
NCT01592240 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01592240 about?
NCT01592240 is a clinical study titled "Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin". To evaluate the Low Density Lipoprotein-Cholesterol (LDL-C) lowering effect of PF-04950615 administered subcutaneously at monthly intervals, or twice monthly intervals in subjects with high cholesterol whose LDL-cholesterol is \>/=80 mg/dL on background treatment with a statin.
What is the current status of trial NCT01592240?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 354 participants. The study started on 2012-07. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01592240?
The interventions under investigation include: PBO (DRUG), 200mg PF-04950615 (RN316) (DRUG), 300mg PF-04950615 (RN316) (DRUG), PF-04950615 (DRUG).
Who is sponsoring clinical trial NCT01592240?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.